{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:55:44Z","timestamp":1790999744726,"version":"4.1.0"},"reference-count":84,"publisher":"Japan Endocrine Society","issue":"10","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K22896"],"award-info":[{"award-number":["JP20K22896"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K08646"],"award-info":[{"award-number":["JP22K08646"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008695","name":"Japan Foundation for Applied Enzymology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJMS2023"],"award-info":[{"award-number":["JPMJMS2023"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej26-0125","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:09:43Z","timestamp":1782252583000},"page":"1095-1106","source":"Crossref","is-referenced-by-count":0,"title":["Inter- and intratumoral heterogeneity of aldosterone-producing adenomas: recent advances and clinical implications"],"prefix":"10.1507","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-3502","authenticated-orcid":false,"given":"Masanori","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, et al. (2017) Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 69: 1811\u20131820.","DOI":"10.1016\/j.jacc.2017.01.052"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Hannemann A, Wallaschofski H (2012) Prevalence of primary aldosteronism in patient\u2019s cohorts and in population-based studies\u2014a review of the current literature. Horm Metab Res 44: 157\u2013162.","DOI":"10.1055\/s-0031-1295438"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, et al. (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101: 1889\u20131916.","DOI":"10.1210\/jc.2015-4061"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, et al. (2018) Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension 71: 530\u2013537.","DOI":"10.1161\/HYPERTENSIONAHA.117.10263"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Rossi GP, Bisogni V, Bacca AV, Belfiore A, Cesari M, et al. (2020) The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int J Cardiol Hypertens 5: 100029.","DOI":"10.1097\/01.hjh.0000745016.79540.85"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, et al. (2020) Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens 38: 1919\u20131928.","DOI":"10.1097\/HJH.0000000000002510"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, et al. (2022) Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J 69: 327\u2013359.","DOI":"10.1507\/endocrj.EJ21-0508"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8 Choi M, Scholl UI, Yue P, Bj\u00f6rklund P, Zhao B, et al. (2011) K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331: 768\u2013772.","DOI":"10.1126\/science.1198785"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, et al. (2013) Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 45: 1055\u20131060.","DOI":"10.1038\/ng.2716"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, et al. (2013) Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 45: 440\u2013444, 444e441\u2013442.","DOI":"10.1038\/ng.2550"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Scholl UI, St\u00f6lting G, Nelson-Williams C, Vichot AA, Choi M, et al. (2015) Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 4: e06315.","DOI":"10.7554\/eLife.06315"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 \u00c5kerstr\u00f6m T, Maharjan R, Sven Willenberg H, Cupisti K, Ip J, et al. (2016) Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci Rep 6: 19546.","DOI":"10.1038\/srep19546"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Zhou J, Azizan EAB, Cabrera CP, Fernandes-Rosa FL, Boulkroun S, et al. (2021) Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. Nat Genet 53: 1360\u20131372.","DOI":"10.1038\/s41588-021-00906-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Fernandes-Rosa FL, Daniil G, Orozco IJ, G\u00f6ppner C, El Zein R, et al. (2018) A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet 50: 355\u2013361.","DOI":"10.1038\/s41588-018-0053-8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Wu X, Azizan EAB, Goodchild E, Garg S, Hagiyama M, et al. (2023) Somatic mutations of CADM1 in aldosterone-producing adenomas and gap junction-dependent regulation of aldosterone production. Nat Genet 55: 1009\u20131021.","DOI":"10.1038\/s41588-023-01403-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Rege J, Bandulik S, Nanba K, Kosmann C, Blinder AR, et al. (2023) Somatic SLC30A1 mutations altering zinc transporter ZnT1 cause aldosterone-producing adenomas and primary aldosteronism. Nat Genet 55: 1623\u20131631.","DOI":"10.1038\/s41588-023-01498-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Spyroglou A, Piaditis GP, Kaltsas G, Alexandraki KI (2021) Transcriptomics, epigenetics, and metabolomics of primary aldosteronism. Cancers (Basel) 13: 5582.","DOI":"10.3390\/cancers13215582"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Scholl UI (2022) Genetics of primary aldosteronism. Hypertension 79: 887\u2013897.","DOI":"10.1161\/HYPERTENSIONAHA.121.16498"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Fernandes-Rosa FL, Boulkroun S, Zennaro MC (2020) Genetic and genomic mechanisms of primary aldosteronism. Trends Mol Med 26: 819\u2013832.","DOI":"10.1016\/j.molmed.2020.05.005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Omata K, Yamazaki Y, Nakamura Y, Anand SK, Barletta JA, et al. (2017) Genetic and histopathologic intertumor heterogeneity in primary aldosteronism. J Clin Endocrinol Metab 102: 1792\u20131796.","DOI":"10.1210\/jc.2016-4007"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21 De Sousa K, Boulkroun S, Baron S, Nanba K, Wack M, et al. (2020) Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma. Hypertension 75: 1034\u20131044.","DOI":"10.1161\/HYPERTENSIONAHA.119.14177"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22 Murakami M, Hara K, Ikeda K, Horino M, Okazaki R, et al. (2024) Single-nucleus analysis reveals tumor heterogeneity of aldosterone-producing adenoma. Hypertension 81: 361\u2013371.","DOI":"10.1161\/HYPERTENSIONAHA.123.21446"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Gong S, Sun N, Meyer LS, Tetti M, Koupourtidou C, et al. (2023) Primary aldosteronism: spatial multiomics mapping of genotype-dependent heterogeneity and tumor expansion of aldosterone-producing adenomas. Hypertension 80: 1555\u20131567.","DOI":"10.1161\/HYPERTENSIONAHA.123.20921"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Yokomoto-Umakoshi M, Fujita M, Umakoshi H, Ogasawara T, Iwahashi N, et al. (2025) Multiomics analysis unveils the cellular ecosystem with clinical relevance in aldosterone-producing adenomas with KCNJ5 mutations. Proc Natl Acad Sci U S A 122: e2421489122.","DOI":"10.1073\/pnas.2421489122"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Tauber P, Penton D, Stindl J, Humberg E, Tegtmeier I, et al. (2014) Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomas. Endocrinology 155: 1353\u20131362.","DOI":"10.1210\/en.2013-1944"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26 Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, et al. (2012) Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 59: 592\u2013598.","DOI":"10.1161\/HYPERTENSIONAHA.111.186478"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Chang YY, Lee BC, Chen ZW, Tsai CH, Chang CC, et al. (2023) Cardiovascular and metabolic characters of KCNJ5 somatic mutations in primary aldosteronism. Front Endocrinol (Lausanne) 14: 1061704.","DOI":"10.3389\/fendo.2023.1061704"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Wu VC, Huang KH, Peng KY, Tsai YC, Wu CH, et al. (2015) Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. Sci Rep 5: 11396.","DOI":"10.1038\/srep11396"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Kitamoto T, Omura M, Suematsu S, Saito J, Nishikawa T (2018) KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma. J Hypertens 36: 619\u2013627.","DOI":"10.1097\/HJH.0000000000001578"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Vilela LAP, Rassi-Cruz M, Guimaraes AG, Moises CCS, Freitas TC, et al. (2019) KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 104: 4695\u20134702.","DOI":"10.1210\/jc.2019-00531"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31 Chang YY, Tsai CH, Peng SY, Chen ZW, Chang CC, et al. (2021) KCNJ5 somatic mutations in aldosterone-producing adenoma are associated with a worse baseline status and better recovery of left ventricular remodeling and diastolic function. Hypertension 77: 114\u2013125.","DOI":"10.1161\/HYPERTENSIONAHA.120.15679"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Chang YY, Pan CT, Chen ZW, Tsai CH, Peng SY, et al. (2021) KCNJ5 somatic mutations in aldosterone-producing adenoma are associated with a greater recovery of arterial stiffness. Cancers (Basel) 13: 4313.","DOI":"10.3390\/cancers13174313"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Meyer LS, Handgriff L, Lim JS, Udager AM, Kinker IS, et al. (2021) Single-center prospective cohort study on the histopathology, genotype, and postsurgical outcomes of patients with primary aldosteronism. Hypertension 78: 738\u2013746.","DOI":"10.1161\/HYPERTENSIONAHA.121.17348"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Scholl UI, Abriola L, Zhang C, Reimer EN, Plummer M, et al. (2017) Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma. J Clin Invest 127: 2739\u20132750.","DOI":"10.1172\/JCI91733"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Wang F, Ma X, Tong A, Zhang Y, Wen J, et al. (2020) The effects of different calcium channel blockers on aldosterone-producing adenoma cells. Front Endocrinol (Lausanne) 11: 260.","DOI":"10.3389\/fendo.2020.00260"},{"key":"36","unstructured":"36 Chu C, Zhao C, Zhang Z, Wang M, Zhang Z, et al. (2017) Transcriptome analysis of primary aldosteronism in adrenal glands and controls. Int J Clin Exp Pathol 10: 10009\u201310018."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Scholl UI, Healy JM, Thiel A, Fonseca AL, Brown TC, et al. (2015) Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clin Endocrinol (Oxf) 83: 779\u2013789.","DOI":"10.1111\/cen.12873"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Bassett MH, Mayhew B, Rehman K, White PC, Mantero F, et al. (2005) Expression profiles for steroidogenic enzymes in adrenocortical disease. J Clin Endocrinol Metab 90: 5446\u20135455.","DOI":"10.1210\/jc.2005-0836"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Kitamoto T, Suematsu S, Yamazaki Y, Nakamura Y, Sasano H, et al. (2016) Clinical and steroidogenic characteristics of aldosterone-producing adenomas with ATPase or CACNA1D gene mutations. J Clin Endocrinol Metab 101: 494\u2013503.","DOI":"10.1210\/jc.2015-3284"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Assi\u00e9 G, Auzan C, Gasc JM, Baviera E, Balaton A, et al. (2005) Steroidogenesis in aldosterone-producing adenoma revisited by transcriptome analysis. J Clin Endocrinol Metab 90: 6638\u20136649.","DOI":"10.1210\/jc.2005-1309"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Kobuke K, Oki K, Gomez-Sanchez CE, Gomez-Sanchez EP, Ohno H, et al. (2018) Calneuron 1 increased Ca<sup>2+<\/sup> in the endoplasmic reticulum and aldosterone production in aldosterone-producing adenoma. Hypertension 71: 125\u2013133.","DOI":"10.1161\/HYPERTENSIONAHA.117.10205"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Wang T, Satoh F, Morimoto R, Nakamura Y, Sasano H, et al. (2011) Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glands. Eur J Endocrinol 164: 613\u2013619.","DOI":"10.1530\/EJE-10-1085"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Williams TA, Monticone S, Crudo V, Warth R, Veglio F, et al. (2012) Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. Hypertension 59: 833\u2013839.","DOI":"10.1161\/HYPERTENSIONAHA.111.188532"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Monticone S, Hattangady NG, Nishimoto K, Mantero F, Rubin B, et al. (2012) Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 97: E1567\u2013E1572.","DOI":"10.1210\/jc.2011-3132"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 \u00c5kerstr\u00f6m T, Willenberg HS, Cupisti K, Ip J, Backman S, et al. (2015) Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas. Endocr Relat Cancer 22: 735\u2013744.","DOI":"10.1530\/ERC-15-0321"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Backman S, \u00c5kerstr\u00f6m T, Maharjan R, Cupisti K, Willenberg HS, et al. (2019) RNA sequencing provides novel insights into the transcriptome of aldosterone producing adenomas. Sci Rep 9: 6269.","DOI":"10.1038\/s41598-019-41525-2"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47 Williams TA, Monticone S, Schack VR, Stindl J, Burrello J, et al. (2014) Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension 63: 188\u2013195.","DOI":"10.1161\/HYPERTENSIONAHA.113.01733"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, et al. (2015) Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol Cell Endocrinol 411: 146\u2013154.","DOI":"10.1016\/j.mce.2015.04.022"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Li X, Wang B, Tang L, Zhang Y, Chen L, et al. (2018) GSTA1 expression is correlated with aldosterone level in KCNJ5-mutated adrenal aldosterone-producing adenoma. J Clin Endocrinol Metab 103: 813\u2013823.","DOI":"10.1210\/jc.2017-00950"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Plaska SW, Liu CJ, Lim JS, Rege J, Bick NR, et al. (2020) Targeted RNAseq of formalin-fixed paraffin-embedded tissue to differentiate among benign and malignant adrenal cortical tumors. Horm Metab Res 52: 607\u2013613.","DOI":"10.1055\/a-1212-8803"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Zhou J, Lam B, Neogi SG, Yeo GS, Azizan EA, et al. (2016) Transcriptome pathway analysis of pathological and physiological aldosterone-producing human tissues. Hypertension 68: 1424\u20131431.","DOI":"10.1161\/HYPERTENSIONAHA.116.08033"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Maniero C, Garg S, Zhao W, Johnson TI, Zhou J, et al. (2017) NEFM (Neurofilament Medium) polypeptide, a marker for zona glomerulosa cells in human adrenal, inhibits D1R (Dopamine D1 Receptor)-mediated secretion of aldosterone. Hypertension 70: 357\u2013364.","DOI":"10.1161\/HYPERTENSIONAHA.117.09231"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Gong S, Tetti M, Kemter E, Peitzsch M, Mulatero P, et al. (2023) TSPAN12 (Tetraspanin 12) is a novel negative regulator of aldosterone production in adrenal physiology and aldosterone-producing adenomas. Hypertension 80: 440\u2013450.","DOI":"10.1161\/HYPERTENSIONAHA.122.19783"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Murakami M, Yoshimoto T, Nakano Y, Tsuchiya K, Minami I, et al. (2016) Expression of inflammation-related genes in aldosterone-producing adenomas with KCNJ5 mutation. Biochem Biophys Res Commun 476: 614\u2013619.","DOI":"10.1016\/j.bbrc.2016.06.007"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, et al. (2012) Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab 97: E819\u2013E829.","DOI":"10.1210\/jc.2011-2965"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Murakami M, Yoshimoto T, Nakabayashi K, Nakano Y, Fukaishi T, et al. (2017) Molecular characteristics of the KCNJ5 mutated aldosterone-producing adenomas. Endocr Relat Cancer 24: 531\u2013541.","DOI":"10.1530\/ERC-17-0117"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Murakami M, Yoshimoto T, Nakabayashi K, Tsuchiya K, Minami I, et al. (2015) Integration of transcriptome and methylome analysis of aldosterone-producing adenomas. Eur J Endocrinol 173: 185\u2013195.","DOI":"10.1530\/EJE-15-0148"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Howard B, Wang Y, Xekouki P, Faucz FR, Jain M, et al. (2014) Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas. J Clin Endocrinol Metab 99: E536\u2013E543.","DOI":"10.1210\/jc.2013-3495"},{"key":"59","doi-asserted-by":"publisher","unstructured":"59 Yoshii Y, Oki K, Gomez-Sanchez CE, Ohno H, Itcho K, et al. (2016) Hypomethylation of CYP11B2 in aldosterone-producing adenoma. Hypertension 68: 1432\u20131437.","DOI":"10.1161\/HYPERTENSIONAHA.116.08313"},{"key":"60","doi-asserted-by":"publisher","unstructured":"60 Kometani M, Yoneda T, Demura M, Aono D, Gondoh Y, et al. (2019) Genetic and epigenetic analyses of aldosterone-producing adenoma with hypercortisolemia. Steroids 151: 108470.","DOI":"10.1016\/j.steroids.2019.108470"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Di Dalmazi G, Morandi L, Rubin B, Pilon C, Asioli S, et al. (2020) DNA methylation of steroidogenic enzymes in benign adrenocortical tumors: new insights in aldosterone-producing adenomas. J Clin Endocrinol Metab 105: dgaa585.","DOI":"10.1210\/clinem\/dgaa585"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Peng KY, Chang HM, Lin YF, Chan CK, Chang CH, et al. (2018) miRNA-203 modulates aldosterone levels and cell proliferation by targeting Wnt5a in aldosterone-producing adenomas. J Clin Endocrinol Metab 103: 3737\u20133747.","DOI":"10.1210\/jc.2018-00746"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Nakano Y, Yoshimoto T, Watanabe R, Murakami M, Fukuda T, et al. (2019) miRNA299 involvement in CYP11B2 expression in aldosterone-producing adenoma. Eur J Endocrinol 181: 69\u201378.","DOI":"10.1530\/EJE-18-0882"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Decmann A, Ny\u00edr\u00f6 G, Darvasi O, Turai P, Bancos I, et al. (2019) Circulating miRNA expression profiling in primary aldosteronism. Front Endocrinol (Lausanne) 10: 739.","DOI":"10.3389\/fendo.2019.00739"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Okamoto K, Sone M, Taura D, Ohno Y, Yamauchi I, et al. (2026) The significance of high expression of circulating miR-222-3p in patients with unilateral primary aldosteronism. J Clin Endocrinol Metab 111: e420\u2013e430.","DOI":"10.1210\/clinem\/dgaf408"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Raman PB, Sharma DC, Dorfman RI, Gabrilove JL (1965) Biosynthesis of C-18-oxygenated steroids by an aldosterone-secreting human adrenal tumor. Metabolism of [4-14C] progesterone, [1,2-3H]11-deoxycorticosterone, and [4-14C] pregnenolone. Biochemistry 4: 1376\u20131385.","DOI":"10.1021\/bi00883a023"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Gordon RD, Hamlet SM, Tunny TJ, Gomez-Sanchez CE, Jayasinghe LS (1986) Distinguishing aldosterone-producing adenoma from other forms of hyperaldosteronism and lateralizing the tumour pre-operatively. Clin Exp Pharmacol Physiol 13: 325\u2013328.","DOI":"10.1111\/j.1440-1681.1986.tb00357.x"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Nakamura Y, Satoh F, Morimoto R, Kudo M, Takase K, et al. (2011) 18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism. J Clin Endocrinol Metab 96: E1272\u2013E1278.","DOI":"10.1210\/jc.2010-2785"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Mulatero P, di Cella SM, Monticone S, Schiavone D, Manzo M, et al. (2012) 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab 97: 881\u2013889.","DOI":"10.1210\/jc.2011-2384"},{"key":"70","doi-asserted-by":"publisher","unstructured":"70 Satoh F, Morimoto R, Ono Y, Iwakura Y, Omata K, et al. (2015) Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension 65: 1096\u20131102.","DOI":"10.1161\/HYPERTENSIONAHA.114.04453"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Eisenhofer G, Dekkers T, Peitzsch M, Dietz AS, Bidlingmaier M, et al. (2016) Mass spectrometry-based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism. Clin Chem 62: 514\u2013524.","DOI":"10.1373\/clinchem.2015.251199"},{"key":"72","doi-asserted-by":"crossref","first-page":"e130356","DOI":"10.1172\/jci.insight.130356","volume":"4","author":"M Murakami","year":"2019","unstructured":"72 Murakami M, Rhayem Y, Kunzke T, Sun N, Feuchtinger A, et al. (2019) <i>In situ<\/i> metabolomics of aldosterone-producing adenomas. JCI Insight 4: e130356.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"73","doi-asserted-by":"publisher","unstructured":"73 Williams TA, Peitzsch M, Dietz AS, Dekkers T, Bidlingmaier M, et al. (2016) Genotype-specific steroid profiles associated with aldosterone-producing adenomas. Hypertension 67: 139\u2013145.","DOI":"10.1161\/HYPERTENSIONAHA.115.06186"},{"key":"74","doi-asserted-by":"publisher","unstructured":"74 Tezuka Y, Yamazaki Y, Kitada M, Morimoto R, Kudo M, et al. (2019) 18-oxocortisol synthesis in aldosterone-producing adrenocortical adenoma and significance of KCNJ5 mutation status. Hypertension 73: 1283\u20131290.","DOI":"10.1161\/HYPERTENSIONAHA.118.12064"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Yang Y, Liu Y, Williams TA, Gao M, Yan Y, et al. (2025) Metabolic phenotypes and fatty acid profiles associated with histopathology of primary aldosteronism. Hypertens Res 48: 1363\u20131378.","DOI":"10.1038\/s41440-025-02143-w"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Williams TA, Gomez-Sanchez CE, Rainey WE, Giordano TJ, Lam AK, et al. (2021) International histopathology consensus for unilateral primary aldosteronism. J Clin Endocrinol Metab 106: 42\u201354.","DOI":"10.1210\/clinem\/dgaa484"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Wu CH, Peng KY, Yang YW, Chen PY, Chen YL, et al. (2026) KCNJ5-negative primary aldosteronism: histopathology and surgical outcomes. Hypertension 83: e26266.","DOI":"10.1161\/HYPERTENSIONAHA.125.26266"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Yamazaki Y, Omata K, Tezuka Y, Ono Y, Morimoto R, et al. (2018) Tumor cell subtypes based on the intracellular hormonal activity in KCNJ5-mutated aldosterone-producing adenoma. Hypertension 72: 632\u2013640.","DOI":"10.1161\/HYPERTENSIONAHA.118.10907"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Nakamura Y, Yamazaki Y, Tezuka Y, Satoh F, Sasano H (2016) Expression of CYP11B2 in aldosterone-producing adrenocortical adenoma: regulatory mechanisms and clinical significance. Tohoku J Exp Med 240: 183\u2013190.","DOI":"10.1620\/tjem.240.183"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Lei Y, Tang R, Xu J, Wang W, Zhang B, et al. (2021) Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol 14: 91.","DOI":"10.1186\/s13045-021-01105-2"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Iwahashi N, Umakoshi H, Seki T, Gomez-Sanchez CE, Mukai K, et al. (2022) Characterization of Aldosterone-producing Cell Cluster (APCC) at single-cell resolution. J Clin Endocrinol Metab 107: 2439\u20132448.","DOI":"10.1210\/clinem\/dgac394"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Le Floch E, Cosentino T, Larsen CK, Beuschlein F, Reincke M, et al. (2022) Identification of risk loci for primary aldosteronism in genome-wide association studies. Nat Commun 13: 5198.","DOI":"10.1038\/s41467-022-32896-8"},{"key":"83","doi-asserted-by":"publisher","unstructured":"83 Huang J, Qin F, Lai X, Yang T, Yu J, et al. (2023) Exploring heterogeneity of tumor immune cells and adrenal cells in aldosterone-producing adenomas using single-cell RNA-seq and investigating differences by sex. Heliyon 9: e14357.","DOI":"10.1016\/j.heliyon.2023.e14357"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Huang J, Qin F, Li J (2026) Single-cell transcriptomic analysis reveals metabolic reprogramming and tumor microenvironment remodeling in aldosterone-producing adenoma. Genomics 118: 111164.","DOI":"10.1016\/j.ygeno.2025.111164"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/10\/73_EJ26-0125\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:38:09Z","timestamp":1790998689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/10\/73_EJ26-0125\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej26-0125","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ26-0125"}}